Overview Biologicals and Immunologicals: Peptide immunomodulators: progress and prospects

References

• FRIDIUN M, NAJJAR VA: Tuftsin: its chemistry, biology, and clinical potential. Grit. Rev. Biochem. MoL Biol. (1989) 24:1-40. Good review of tuftsin
   Google Scholar
• BIONDI L, FILIRA F, ROCCHI R, TZEHOVAL E, FRIDIUN M: Synthesis and biological activity of [L-hy-droxyproliner-tuftsin analogue and its a- or 13-0-D-glu-cosylated derivatives. Int. J. Peptide Protein Res. (1993) 41:43–51.
   PubMedGoogle Scholar
• WARNER E, SULKES A, GEZ E, UZIELY B, BEN-BARUCH N, BEN-YOSEF R, BIRAN S, CATANE R: Combined immuno-therapy and chemotherapy with tuftsin plus cyclophos-phamide in the treatment of non-small-cell carcinoma of the lung. Chemioterapia (1987) 6(Suppl 2):706–708.
   PubMedGoogle Scholar
• MTLI.FR FAP: Immunological function of the thymus. Lancet (1961) 2:748–749.
   PubMedGoogle Scholar
• GOOD RA, DALMASSO AP, MARTINEZ C, ARCHER OK, PIERCE JC, PAPERMASTER BW: The role of the thymus in development of immunologic capacity in rabbits and mice. J. E. Med. (1962) 116:773–803.
   PubMed Web of Science ®Google Scholar
• VAN EW1JK W: T-cell differentiation is influenced by thymic microenvironments. Annu. Rev. Immunol. (1991) 9:591–615.
   PubMedGoogle Scholar
• OSOBA D, MILLER JFAP: Evidence for a humoral thymus factor responsible for the maturation of immunological faculty. Nature (1963) 199:653-654. Original experiments suggesting secretion of humorol immunol-modulatory factor from the thymus (see also 8).
   Google Scholar
• LEVEY RH, TRAININ N, LAW LW: Evidence for function of thymic tissue in diffusion chambers implanted in neonatally thymectomized mice. Preliminary Report. J. Natl. Cancer Inst. (1963) 31:199–206.
   Google Scholar
• GOLDSTEIN AL, LOW TLK, McADOO M, McCLURE J, THURMAN GB, ROSSIO J, LAI C-Y, CHANG D, WANG S-S, HARVEY C, RAMEL AH, MEIENHOFER J: Thymosin al: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl. Acad. Sci. (1977) 74:725-729. 38.
   Google Scholar
• SZABO P, WEKSLER ME: Short analytical review. Is thy-mosin a-1 a thymic hormone? din. Immunol. Immu-nopathol. (1992) 65:195–200.
   PubMedGoogle Scholar
• SCHULOF RS, LLOYD MJ, CLEARY PA, PALASZYNSKI SR, MM DA, COX JW, ALABASTER 0, GOLDSTEIN AL: A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-al in patients with lung cancer. J. Biol. Response Mod. (1985) 4:147–158.
   PubMedGoogle Scholar
• DELMAN RO, BEAUREGARD J, ROYSTON I, ZAVANELLI MI: Phase 11 trial of thymosin fraction 5 and thymosin alpha 1.1. Biol. Response Mod. (1987) 6:263–267.
   PubMedGoogle Scholar
• GRAVENSTEIN S, DUTHIE EH, MR LFR BA, ROECKER E, DRINKA P, PRATHIPATI K, ERSHLER W: Augmentation of Influenza antibody response in elderly men by thy-mosin alpha one. A double-blind placebo-controlled clinical study. J. Am. Gerieur. Soc. (1989) 37:1–8.
   Google Scholar
• MUTCHNICK MG, APPELMAN HD, CHUNG HT, ARAGONA E, GUPTA TP, CUMMINGS GD, WAGGONER JG, HOOFNA-GLE JH, SHAFRITZ DA: Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial Hepatology (1991) 14:409–415.
   Google Scholar
• BACH J-F, DARDENNE M: Studies on thymus products. IL Demonstration and characterization of a circulating thymic hormone. Immunology (1973) 25:353–366.
   Google Scholar
• BACH J-F, DARDENNE M, PLEAU J-M: Biochemical char-acterization of a serum thymic factor. Nature (1977) 266:55–56.
   PubMedGoogle Scholar
• FAURE GC, BENE MC, THOMAS P, TAMIS1ER JN: An open trial of thymulin (FIS-Zn) in rheumatoid arthritis pa-tients: sequential clinical and immunological follow-up. din. E:cp. Rheumatol. (1987) 5:291–293.
   Google Scholar
• AMOR B, DOUGADOS M, MERY C, DARDENNE M, BACH J-F: Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. Ann. Rheum. Dis. (1987) 46:549–554.
   PubMedGoogle Scholar
• SARGENT IL, SALAMAN MR, VALDIMARSSON H: Dual ac-tion of leucocyte dialysates and of thymosin on the recovery of sheep- cell-rosetting capacity in trypsinized human lymphocytes. Clin. Exp. Immunol. (1982) 47:183–190.
   PubMedGoogle Scholar
• BURSTEIN Y, BUCHNER V, PECHT M, TRAININ N: Thymichumoral factor y/: purification and amino acid se-quence of an immunoregulatory peptide From calf thymus. Biochemistry (1988) 27:4066–4071.
   PubMed Web of Science ®Google Scholar
• HANDZEL ZT, BURSTEIN Y, BUCHNER V, PECHT M, TRAININ N: Inununomodulation of T-cell deficiency in humans by thymic humoral factor: from crude extract to synthetic thymic humoral factor-72. J. Biol. Response Mod. (1990) 9:269–278.
   PubMedGoogle Scholar
• GOLDSTEIN G, SCHEID MP, BOYSE EA, SCHLESINGER DH, VAN WAUWE J: A synthetic pentapeptide with biological activity characteristic of the thymic hormone thy-mopoietin. Science (1979) 202:1309–1310.
   Google Scholar
• GOLDSTEIN G: Isolation of bovine thymin: a polypep-tide hormone of the thymus. Nature (1974) 247:11–14.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN G: Thytnitis and myasthenia gravis. Lancet (1966) 2:1164–1167.
   PubMedGoogle Scholar
• GOLDSTEIN G: The thymus and neuromuscular func-tion. A substance in thymus which causes myositis and myasthenic neuromuscular block in guinea pigs. Lancet (1968) 2:119–122.
   Google Scholar
• GOLDSTEIN G, HOFMANN WW: Electrophysiological changes similar to those of myasthenia gravis in rats with experimental autoimmune thymitis. j Neurol. Neurosutg. Psychiatry (1968) 31:453–459.
   PubMedGoogle Scholar
• GOLDSTEIN G, HOFMANN WW: Endocrine function ofthe thymus affecting neuromuscular transmission. din. Exp. Immunol. (1969) 4:181–189.
   PubMedGoogle Scholar
• SCHLESINGER DH, GOLDSTEIN G: The amino acid se-quence of thymopoietin 11. Cell (1975) 5:361–365.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN G, SCHLESINGER DH: Thymopoietin and myasthenia gravis: neostigmine-responsive neuromus-cular block produced in mice by a synthetic peptide fragment of thymopoietin. Lancet (1975) 2:256–262.
   PubMedGoogle Scholar
• SCHEID MP, GOLDSTEIN G, BOYSE EA: The generation and regulation of lymphocyte populations. Evidence from differentiative induction systems in vitro. J. Exp. Med. (1978) 147:1727–1743.
   PubMed Web of Science ®Google Scholar
• SUNSHINE GH, BASCH RS, COFFEY RG, COHEN KW, GOLDSTEIN G, HADDEN JW: Thymopoietin enhances the allogeneic response and cyclic GMP levels of mouse peripheral, thymus-derived lymphocytes. J. Immunol. (1978) 120:1594–1599.
   PubMedGoogle Scholar
• WEKSLER ME, INNES JB, GOLDSTEIN G: Immunologicalstudies of aging. IV. The contribution of thymic involu-tion to the immune deficiencies of aging mice and reversal with thymopoietin3246. J. Exp. Med. (1978) 148:996–1006.
   Google Scholar
• LAU CY, GOLDSTEIN G: Functional effects of thymopoie-tin 32.36 (TP-5) on cytotoxic lymphocyte precursor units (CLP-U). L Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation. J. Immu-nol. (1980) 124:1861–1865.
   Google Scholar
• LAU CY, FREESTONE JA, GOLDSTEIN G: Effect of thy-mopoietin pentapeptide (TP5) on autoimmunity. L TP5 suppression of induced erythrocyte autoantibodies in C311 mice. J. Immunol. (1980) 125:1634–1638.
   Google Scholar
• LAU CY, WANG EY, GOLDSTEIN G: Studies of thymopoie-tin pentapeptide (TP5) on experimental tumors. L 1P5 relieves immunosuppression in tumor-bearing mice. Cell. Immunol. (1982) 66:217–232.
   Google Scholar
• BAKER B, VIAMONTES G, AUDHYA T, GOLDSTEIN G: Selected human T-cell lines respond to thymopoietin with intracr16112r cyclic GMP elevations. Immunophar-macology (1988) 16:115–122.
   PubMedGoogle Scholar
• ZEVIN-SONKIN D, ILAN E, GUTHMANN D, RISS J, THEO-DOR L, SHOHAM J: Molecular cloning of the bovine thymopoietin gene and its expression in different calf tissues: evidence for a predominant expression in thy-mocytes. Immunol. Lett. (1992) 31:301–309.
   PubMedGoogle Scholar
• SUNDAL E: Thymopentin prophylactic treatment in patients with recurrent respiratory infections. Brit. J. din. Practice (1993) 47:198-204. Overview of a number of open studies.
   Google Scholar
• KANG K, COOPER KD, HANIFIN JM: Thymopoietin pen-tapeptide (TP-5) improves clinical parameters and lym-phocyte subpopulations in atopic dermatitis. J. Am. Acad. Dermatol. (1983) 8:372–377.
   PubMedGoogle Scholar
• LEUNG DYM, HIRSCH RI, SCHNEIDER L, MOODY C, TAKAOKA R, LI SH, MEYERSON LA, MARIAM SG, GOLD-STEIN G, HANIFIN JM: Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin. Immunol. (1990) 85:927-933. 29.
   Google Scholar
• HANE10E E, BOLLA K, DEGREEF H, DJAWARI D, DE-MAUBEUGE J, MOLIN L, PANCONESI E, SCHOPF E, STENGEL R, STINGL G, WOLFF K, WUTHRICH B: The effect of thymopentin treatment on the relapse rate in fre-quently relapsing herpes simplex virus Infections. Int. J. Ctn. Pharm. Res. (1984) 4:439–443.
   PubMedGoogle Scholar
• BOLLA K, DJAWARI D, KOKOSCHKA EM, PETRES J, LIDENS, GONSETH R, AMBLARD P, BERNENGO MG, BONERANDI JJ, CLAUDY A, DEGREEF H, DEMAUBEUGE J, MEYNADLER J, SAURAT JH, SCHOPF E, HOBEL W, CASTAIGNE JP, SUNDAL E: Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. Suru. Im-munol. Res. (1985) 4(Suppl 1):37–47.
   PubMedGoogle Scholar
• BOLLA K, DEMAUBEUGE J, LIDEN S, BONERANDI J, SUN-DAL E: Treatment of genital herpes simplex infections with thymopentin: a double-blind placebo-controlled study. Int. J. lmmunotherapy (1988) 4:219–227.
   Google Scholar
• MALAISE M, FRANCH1MONT P, HAUWAERT C, DAN-NESKIOLD-SAMSOE B, GROSS D, GERBER H, GERSCHPACHER H, BOLLA K: Interim results on the clinical effects of iv administered thymopentin in active rheumatoid arthritis. Int.J. Gun. Pharm. Res. (1984) 4:451–457.
   PubMedGoogle Scholar
• LEMMEL EM, BACH GL, BOLTEN W, BRACKERTZ D, FAHMYZ, MATTERN H, STROEHMANN I, WITTENBORG A: Ina-munoregulating therapy of rheumatoid arthritis with thymopentin: a multi-center placebo-controlled study of 119 patients. Dtsch. Med. Wschr. (1986) 113:1772–1776.
   Google Scholar
• ICANTHARIA BK, GOULDING NJ, HALL ND, DAVIES J,MADDISON PJ, BACON PA, FARR M, WOJTULEWSKI JA, ENGLEHART KM, LIYANAGE SP, COX NL: Thymopentin (TP-5) in the treatment of rheumatoid arthritis. Br. J Rheumatol. (1989) 28:118–123.
   PubMedGoogle Scholar
• CONANT MA, CALABRESE LH, THOMPSON SE, POIESZ BJ,RASHEED S, HIRSCH RL, MEYERSON LA, KREMER AB, WANG CC, GOLDSTEIN G: Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of a double-blind, placebo-controlled study. AIDS (1992) 6:1335–1339.
   PubMedGoogle Scholar
• BERNENGO MG, DOVEIL GC, MEREGALLI M, APPINO A,MASSOBRIO R: Inununomodulation and Sezary syn-drome experience with thymopentin (TP-5). Br.J. Der-matol. (1988) 119:207–221.
   Google Scholar
• BERNENGO MG, APPINO A, BERTERO M, NOVELLI M, FIERRO MT, DOVELL GC, LISA F: Thymopentin in seTgry syndrome. J. Natl. Cancer Inst. (1992) 84:1341–1346.
   PubMedGoogle Scholar
• HAHN GS: Immunoglobulin-derived drugs. Nature (1986)324:283–284.
   Google Scholar
• WERNER GH: Natural and synthetic peptides (other than neuropeptides) endowed with immunomodulating ac-tivities. Immunol. Lett. (1987) 16:363–370.
   PubMedGoogle Scholar
• HADDEN JW: Lmmunostimulants. Immunol. Today(1993) 14:275–280.
   Google Scholar
• GEENEN V, CORMANN-GOFFIN N, MARTENS H, VAN-DERSMISSEN E, ROBERT F, BENHIDA A, LEGROS J-J, MAR-TIAL J, FRANCHIMONT P: Thymic neurohypophysial-related peptides and T-cell selection. Regul. Pept. (1993) 45:273–278.
   PubMedGoogle Scholar
• FRIEDMANN N: Thymopentin: safety overview. Suru. Immunol. Res. (1985) 4(Suppl 1):139–148.
   PubMedGoogle Scholar